Australia - angielski - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; sodium starch glycollate; iron oxide yellow; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - treatment of postmenopausal women with hormone receptor positive breast cancer (see "clinical trials"). the safety and efficacy of neoadjuvant use has not been established. letrozole is not indicated in hormone receptor negative disease.

Kanada - angielski - Health Canada

teva canada limited - letrozole - tablet - 2.5mg - letrozole 2.5mg - antineoplastic agents

Kanada - angielski - Health Canada

meliapharm inc - letrozole - tablet - 2.5mg - letrozole 2.5mg - antineoplastic agents

Kanada - angielski - Health Canada

actavis pharma company - letrozole - tablet - 2.5mg - letrozole 2.5mg - antineoplastic agents

Kanada - angielski - Health Canada

taro pharmaceuticals inc - letrozole - tablet - 2.5mg - letrozole 2.5mg - antineoplastic agents

Kanada - angielski - Health Canada

fresenius kabi canada ltd - letrozole - tablet - 2.5mg - letrozole 2.5mg - antineoplastic agents

Kanada - angielski - Health Canada

pro doc limitee - letrozole - tablet - 2.5mg - letrozole 2.5mg - antineoplastic agents

Australia - angielski - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate; maize starch; magnesium stearate; lactose monohydrate; titanium dioxide; macrogol 8000; hypromellose; triacetin; iron oxide yellow; iron oxide red; quinoline yellow aluminium lake; polydextrose - for the treatment of postmenopausal women with hormone receptor positive breast cancer. the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch; sodium starch glycollate type a; colloidal anhydrous silica; hypromellose; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; macrogol 400 - indicated for the treatment of post menopausal women with hormone receptor positive breast cancer. . the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; sodium starch glycollate; microcrystalline cellulose; hypromellose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; iron oxide yellow; macrogol 400 - for the treatment of postmenopausal women with hormone receptor positive breast cancer (see clinical trials). the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.